Project cooperationUpdated on 9 April 2026
ASPER2
About
ASPER2 is a therapeutic oligonucleotide based on the ESiNAR-X platform, intended for patients with gradually progressive chronic kidney disease accompanied by renal fibrosis.
Status: Finished pre-clinical validation
We are seeking investments and partnerships to support the execution of clinical trials.
Similar opportunities
Project cooperation
Next-Gen Diagnostics for CKM & CKD Management and Therapy Development
- Research
- Execution
- Technical
- Healthcare
- EU projects
- Biotech, Pharma and Cosmetics
- Partner looking for consortium
- Food, Beverages and Agriculture
Ming Zou
Chief Medical Officer at Quant Biomarkers
Basel, Switzerland